GT Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
GT Biopharma, Inc. (GTBP) filed a Current Report on Form 8-K on March 1, 2026. The Company, incorporated in Delaware and operating as a fully remote entity since July 1, 2024, is reporting a material accounting error requiring the restatement of its interim financial statements for the quarters ended June 30, 2025, and September 30, 2025. The error stems from the misclassification of "Greenshoe Rights" associated with Series L 10% Convertible Preferred Stock issued in May 2025.
Key Financial Metrics and Restatement Impact
The filing details significant adjustments to the balance sheet and statements of operations due to the reclassification of Greenshoe Rights from equity to a liability under ASC 480, followed by a subsequent reclassification back to equity upon a waiver of redemption rights in September 2025.
- Balance Sheet (June 30, 2025): Total Liabilities increased by $28.736 million to $31.043 million. Total Stockholders' Equity (Deficit) decreased by $28.736 million to a deficit of $(25.875) million.
- Balance Sheet (September 30, 2025): The Greenshoe Rights liability was extinguished. Additional Paid-in Capital increased by $17.323 million to $721.095 million, while Accumulated Deficit increased by $17.323 million to $(718.102) million.
- Net Loss (Three Months Ended June 30, 2025): Restated Net Loss attributable to common stockholders increased from $(1.518) million to $(30.254) million due to a $28.736 million loss on initial recognition of the liability.
- Net Loss (Three Months Ended Sept 30, 2025): Restated Net Loss attributable to common stockholders improved from $(3.258) million to a Net Income of $4.097 million, driven by an $11.413 million gain from the change in fair value of the liability and a $4.058 million deemed dividend adjustment.
- Cash Flow: The restatement had no impact on net cash provided by or used in operating, investing, or financing activities for the affected periods.
Material Changes Versus Prior Periods
The primary material change is the correction of the accounting treatment for the Greenshoe Rights. Originally reported as equity, these rights were reclassified as a liability because redemption provisions could require cash settlement upon events outside the Company's control. This reclassification resulted in:
- A significant increase in reported liabilities and a corresponding decrease in equity for the period ended June 30, 2025.
- Volatility in reported Net Loss and Net Loss Per Share (EPS) for the second and third quarters of 2025.
- EPS for the three months ended June 30, 2025, worsened from $(0.55) to $(10.92).
- EPS for the three months ended September 30, 2025, improved from $(0.83) to $1.04.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, revenue projections, or management commentary on future operational outlook. The primary risk disclosed is the non-reliance on previously issued financial statements for the quarters ended June 30, 2025, and September 30, 2025. The Company has concluded that these interim reports may no longer be relied upon and will file amended Forms 10-Q/A to restate the financial data. The audit committee, in consultation with management and the independent auditor Weinberg & Company, P.A., confirmed the error.
Investor Verification Checklist
- Verify the upcoming filing of Forms 10-Q/A for the quarters ended June 30, 2025, and September 30, 2025.
- Review the full 2025 Form 10-K for the complete restated consolidated financial data.
- Confirm the status of the Series L 10% Convertible Preferred Stock and the specific terms of the redemption rights waiver effective in September 2025.
- Assess the impact of the $28.736 million liability recognition and subsequent $17.323 million reclassification to equity on the Company's capital structure and solvency ratios.
- Note that the filing does not provide clear values for revenue, as the Company appears to be in a pre-revenue or development stage with losses driven by operations and accounting adjustments.